Attached files

file filename
8-K - FROM 8-K - ALERE INC.d869295d8k.htm

Exhibit 99.1

 

LOGO

ALERE INC. ANNOUNCES

FOURTH QUARTER 2014 RESULTS

 

 

WALTHAM, MA…February 10, 2015…Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, announced its financial results for the quarter ended December 31, 2014.

Namal Nawana, Chief Executive Officer and President of Alere said, “We made substantial progress in the fourth quarter in refocussing Alere as the global leader in rapid diagnostics and delivering against our financial plans. Successfully closing the Alere Health divestiture in early January enabled us to substantially reduce our debt, and we continue to pursue the divestiture of other non-core assets. Importantly, we achieved 1.9% adjusted organic growth during the fourth quarter of 2014 driven by strong international sales growth. We also executed on our planned cost base change successfully in the fourth quarter of 2014, positioning us well for margin expansion in 2015.”

Financial results for the fourth quarter of 2014:

 

    As a result of our divestiture of Alere Health in early January 2015, the financial results presented for all periods reflect the reclassification of the Alere Health business as a discontinued operation.

 

    Net revenue of $666.9 million for the fourth quarter of 2014, compared to $673.2 million for the fourth quarter of 2013. Non-GAAP adjusted net revenue was $667.1 million for the fourth quarter of 2014, compared to $673.6 million for the fourth quarter of 2013.

 

    Net loss from continuing operations of $27.0 million attributable to common shareholders of Alere Inc., and respective net loss per diluted common share of $0.32 for the fourth quarter of 2014, compared to net loss from continuing operations of $4.4 million attributable to common shareholders of Alere Inc., and respective net loss per diluted common share of $0.06 for the fourth quarter of 2013.

 

    Non-GAAP adjusted net income from continuing operations attributable to common shareholders of Alere Inc. per diluted common share of $0.60 for the fourth quarter of 2014, compared to non-GAAP adjusted net income from continuing operations attributable to common shareholders per diluted common share of $0.63 for the fourth quarter of 2013.


    Net product and services revenue from our Professional Diagnostics segment was $598.7 million in the fourth quarter of 2014, compared to net product and services revenue of $600.7 million in the fourth quarter of 2013. Non-GAAP adjusted net product and services revenue from our Professional Diagnostics segment was $599.0 million in the fourth quarter of 2014, compared to non-GAAP adjusted net product and services revenue of $601.1 million in the fourth quarter of 2013.

 

    U.S. influenza and meter-based Triage product revenues were $25.5 million and $17.8 million, respectively, for the fourth quarter of 2014, compared to $20.9 million and $17.7 million, respectively, for the fourth quarter of 2013.

 

    Excluding the impact of the change in U.S. influenza revenues and the impact on revenues from the U.S. meter-based Triage product sales, currency-adjusted organic growth in our Professional Diagnostics segment was 1.9%. This increase reflects a 4.5% decrease in adjusted U.S. revenues, compared to the fourth quarter of 2013, offset by a 7.6% increase in our international business. The decrease in the U.S. business principally relates to lower revenues from INRatio sales and to lower pain management revenues in our Toxicology business.

 

    Net product and services revenue from our Health Information Solutions segment was $34.7 million in the fourth quarter of 2014, compared to $30.8 million in the fourth quarter of 2013, reflecting growth in our Alere Home Monitoring patient self-testing services from $25.5 million in the fourth quarter of 2013 to $30.0 million in the fourth quarter of 2014.

 

    Gross margin was 46.5% of net revenue in the fourth quarter of 2014, compared to 50.8% in the fourth quarter of 2013. Non-GAAP adjusted gross margins, which exclude from cost of net revenue amortization of acquisition-related intangibles, stock-based compensation expense, restructuring charges, and non-cash charges associated with acquired inventory, was 50.0% of non-GAAP adjusted net revenue in the fourth quarter of 2014, compared to 53.6% in the fourth quarter of 2013 and 49.8% in the third quarter of 2014.

 

    Non-GAAP adjusted selling, general and administrative expenses were $176.4 million or 26.4% of adjusted net revenue in the fourth quarter of 2014, compared to $190.6 million or 28.3% of adjusted net revenue in the fourth quarter of 2013. Non-GAAP adjusted research and development expense was $25.6 million, or 3.8% of adjusted net revenue, compared to $35.7 million, or 5.3% of adjusted net revenue, in the fourth quarter of 2013.


    Non-GAAP adjusted EBITDA from continuing operations for the fourth quarter of 2014 was $155.4 million, which reflects adjustments to add back non-interest related restructuring charges of $21.6 million, $0.2 million of acquisition-related costs and $5.8 million of costs associated with potential business dispositions. On a last-twelve-months basis, our non-GAAP adjusted EBITDA from continuing operations, with restructuring, acquisition and other costs added back, was $562.7 million.

The Company’s GAAP results for continuing operations for the fourth quarter of 2014 exclude $0.3 million of revenue associated with acquired software license contracts that are not recognized due to business combination accounting rules and include $60.8 million of amortization, $21.6 million of restructuring charges, $4.7 million of stock-based compensation expense, $0.2 million of acquisition-related costs recorded in accordance with ASC 805, Business Combinations, $5.8 million of costs associated with potential business dispositions, $0.4 million of interest expense recorded in connection with fees paid for certain debt modifications, $0.2 million in compensation charges and $0.1 million of related interest accretion associated with acquisition-related contingent consideration obligations and $7.1 million in impairment and gain (loss) on dispositions, net, offset by the reversal of $4.8 million of expense recorded for fair value adjustments to acquisition-related contingent consideration.

The Company’s GAAP results for continuing operations for the fourth quarter of 2013 exclude $0.5 million of revenue associated with acquired software license contracts that are not recognized due to business combination accounting rules and include amortization of $70.5 million, $4.2 million of restructuring charges, $6.7 million of stock-based compensation expense, $1.3 million of acquisition-related costs recorded in accordance with ASC 805, Business Combinations, $6.1 million of costs associated with potential business dispositions, $0.4 million of interest expense recorded in connection with fees paid for certain debt modifications, $0.8 million in compensation charges and $0.1 million of related interest accretion associated with acquisition-related contingent consideration obligations, a $0.6 million charge associated with the write-up to fair market value of inventory acquired in connection with the acquisition of Epocal Inc., $0.1 million of costs associated with the proxy contest, offset by an $0.8 million reduction in the loss on disposition of our Spinreact, S.A. subsidiary located in Spain and $1.6 million of income recorded for fair value adjustments to acquisition-related contingent consideration.


Detailed reconciliations of the non-GAAP financial measures presented in this release to the most directly comparable financial measures under GAAP, as well as a discussion regarding these non-GAAP financial measures, are included in the schedules to this press release.

The Company will host a conference call beginning at 8:30 a.m. (Eastern Time) today, February 10, 2015, to discuss these results, as well as other corporate matters. During the conference call, the Company may answer questions concerning business and financial developments and trends and other business and financial matters. The Company’s responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed.

The conference call will be webcast live on the Investor Relations section of Alere’s website or accessed directly through the following link: http://www.videonewswire.com/event.asp?id=101458.

To access the conference call, please use the following dial-in numbers and access code 9692678:

US (toll-free): 1-888-317-6003

International: 1-412-317-6061

Canada (toll-free): 1-866-284-3684

A replay will be available approximately one hour after the conclusion of the call and will remain available for a period of seven days following the call. To hear a replay of the conference call, please use the following dial-in numbers and replay code 10059719 (available for seven days):

US (toll-free): 1-877-344-7529

International: 1-412-317-0088

Canada (toll-free): 1-855-669-9658

The replay will also be available via online webcast at http://www.videonewswire.com/event.asp?id=101458 or via the Investor Relations section of the Alere website for a period of 60 days following the call.

Additionally, reconciliations to non-GAAP financial measures not included in this press release that may be discussed during the call will also be available at the Alere website (http://www.alere.com/us/en/about/investor-relations/events.html) under the Earnings Calls and Releases section shortly before the conference call begins and will continue to be available on this website.


For more information about Alere, please visit our web site at http://www.alere.com.

About Alere

Because Knowing now matters™, Alere delivers reliable and actionable information through rapid diagnostic tests, resulting in better clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for infectious disease, cardiometabolic disease and toxicology. For more information on Alere, please visit www.alere.com.

###

Contact

Juliet Cunningham

Vice President, Investor Relations

858.805.2232

ir@alere.com


Alere Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

 

     Three Months Ended December 31,  
     2014     2013  

Net product sales and services revenue

   $ 661,806      $ 659,039   

License and royalty revenue

     5,051        14,116   
  

 

 

   

 

 

 

Net revenue

     666,857        673,155   

Cost of net revenue

     356,526        331,217   
  

 

 

   

 

 

 

Gross profit

     310,331        341,938   

Gross margin

     47     51

Operating expenses:

    

Research and development

     29,973        38,324   

Selling, general and administrative

     237,793        258,002   

Impairment and gain (loss) on dispositions, net

     7,104        (761
  

 

 

   

 

 

 

Operating income

     35,461        46,373   

Interest and other income (expense), net

     (55,889     (56,293
  

 

 

   

 

 

 

Loss from continuing operations before provision (benefit) for income taxes

     (20,428     (9,920

Provision (benefit) for income taxes

     4,836        (7,082
  

 

 

   

 

 

 

Loss from continuing operations before equity earnings of unconsolidated entities, net of tax

     (25,264     (2,838

Equity earnings of unconsolidated entities, net of tax

     3,793        4,205   
  

 

 

   

 

 

 

Loss from continuing operations

     (21,471     1,367   

Income (loss) from discontinued operations, net of tax

     (1,444     (4,679
  

 

 

   

 

 

 

Net loss

     (22,915     (3,312

Less: Net income (loss) attributable to non-controlling interests

     166        375   
  

 

 

   

 

 

 

Net loss attributable to Alere Inc. and Subsidiaries

     (23,081     (3,687

Preferred stock dividends

     (5,367     (5,367
  

 

 

   

 

 

 

Net loss available to common stockholders

   $ (28,448   $ (9,054
  

 

 

   

 

 

 

Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:

    

Loss from continuing operations

   $ (0.32   $ (0.06

Income (loss) from discontinued operations

     (0.02     (0.05
  

 

 

   

 

 

 

Net loss per common share

   $ (0.34   $ (0.11
  

 

 

   

 

 

 

Weighted average shares - basic and diluted

     83,586        81,913   
  

 

 

   

 

 

 


Alere Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

 

     Year Ended December 31,  
     2014     2013  

Net product sales and services revenue

   $ 2,565,640      $ 2,592,633   

License and royalty revenue

     21,050        27,229   
  

 

 

   

 

 

 

Net revenue

     2,586,690        2,619,862   

Cost of net revenue

     1,364,786        1,297,485   
  

 

 

   

 

 

 

Gross profit

     1,221,904        1,322,377   

Gross margin

     47     50

Operating expenses:

    

Research and development

     144,828        159,053   

Selling, general and administrative

     975,910        997,796   

Impairment and gain (loss) on dispositions, net

     7,742        5,124   
  

 

 

   

 

 

 

Operating income

     93,424        160,404   

Interest and other income (expense), net

     (211,924     (266,605
  

 

 

   

 

 

 

Loss from continuing operations before provision (benefit) for income taxes

     (118,500     (106,201

Provision (benefit) for income taxes

     66,722        (35,359
  

 

 

   

 

 

 

Loss from continuing operations before equity earnings of unconsolidated entities, net of tax

     (185,222     (70,842

Equity earnings of unconsolidated entities, net of tax

     17,509        17,443   
  

 

 

   

 

 

 

Loss from continuing operations

     (167,713     (53,399

Income (loss) from discontinued operations, net of taxes

     2,637        (16,879
  

 

 

   

 

 

 

Net loss

     (165,076     (70,278

Less: Net income (loss) attributable to non-controlling interests

     30        976   
  

 

 

   

 

 

 

Net loss attributable to Alere Inc. and Subsidiaries

     (165,106     (71,254

Preferred stock dividends

     (21,293     (21,293
  

 

 

   

 

 

 

Net loss available to common stockholders

   $ (186,399   $ (92,547
  

 

 

   

 

 

 

Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:

    

Loss from continuing operations

   $ (2.28   $ (0.92

Income (loss) from discontinued operations

     0.03        (0.21
  

 

 

   

 

 

 

Net loss per common share

   $ (2.25   $ (1.13
  

 

 

   

 

 

 

Weighted average shares - basic and diluted

     82,938        81,542   
  

 

 

   

 

 

 


Alere Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands)

 

     December 31,
2014
     December 31,
2013
 

ASSETS

     

CURRENT ASSETS:

     

Cash and cash equivalents

   $ 378,461       $ 355,431   

Restricted cash

     37,571         3,458   

Marketable securities

     259         858   

Accounts receivable, net

     466,106         489,392   

Inventories, net

     365,165         362,167   

Prepaid expenses and other current assets

     221,140         184,287   

Assets held for sale

     306,865         355,530   
  

 

 

    

 

 

 

Total current assets

     1,775,567         1,751,123   

PROPERTY, PLANT AND EQUIPMENT, NET

     456,767         468,232   

GOODWILL AND OTHER INTANGIBLE ASSETS, NET

     4,256,676         4,633,803   

RESTRICTED CASH - NON-CURRENT

     —           29,370   

DEFERRED FINANCING COSTS AND OTHER ASSETS, NET

     228,030         178,286   
  

 

 

    

 

 

 

Total assets

   $ 6,717,040       $ 7,060,814   
  

 

 

    

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

     

CURRENT LIABILITIES:

     

Short-term debt and current portions of long-term debt and capital lease obligations

   $ 93,116       $ 55,074   

Liabilities related to assets held for sale

     126,441         136,920   

Other current liabilities

     549,648         520,612   
  

 

 

    

 

 

 

Total current liabilities

     769,205         712,606   
  

 

 

    

 

 

 

LONG-TERM LIABILITIES:

     

Long-term debt and capital lease obligations, net of current portions

     3,631,945         3,786,030   

Deferred tax liabilities

     363,877         329,249   

Other long-term liabilities

     164,925         150,081   
  

 

 

    

 

 

 

Total long-term liabilities

     4,160,747         4,265,360   
  

 

 

    

 

 

 

TOTAL EQUITY

     1,787,088         2,082,848   
  

 

 

    

 

 

 

Total liabilities and equity

   $ 6,717,040       $ 7,060,814   
  

 

 

    

 

 

 


Alere Inc. and Subsidiaries

Reconciliation to Non-GAAP Adjusted Operating Results

(in thousands, except per share amounts)

 

     Three Months Ended December 31,  
     2014     2013  

Reconciliation to Non-GAAP Adjusted Operating Income (1)

    

Operating income

   $ 35,461      $ 46,373   

Adjustment related to acquired software license contracts

     285        470   

Amortization of acquisition-related intangible assets

     60,686        70,347   

Restructuring charges

     21,622        4,218   

Stock-based compensation expense

     4,701        6,748   

Compensation charges associated with acquisition-related contingent consideration obligations

     182        762   

Acquisition-related costs

     179        1,315   

Fair value adjustments to acquisition-related contingent consideration

     (4,765     (1,559

Non-cash charge associated with acquired inventory

     —          624   

Costs associated with potential business dispositions

     5,802        6,134   

Costs associated with proxy contest

     —          58   

Impairment and gain (loss) on dispositions, net

     7,104        (761
  

 

 

   

 

 

 

Non-GAAP adjusted operating income

   $ 131,257      $ 134,729   
  

 

 

   

 

 

 
     Three Months Ended December 31,  
     2014     2013  

Reconciliation to Non-GAAP Adjusted Net Income (1)

    

Net loss available to common stockholders

   $ (28,448   $ (9,054

Adjustment related to acquired software license contracts

     285        470   

Amortization of acquisition-related intangible assets

     60,689        70,289   

Restructuring charges

     21,630        4,231   

Stock-based compensation expense

     4,701        6,748   

Compensation charges associated with acquisition-related contingent consideration obligations

     182        762   

Acquisition-related costs

     179        1,315   

Fair value adjustments to acquisition-related contingent consideration

     (4,765     (1,559

Non-cash charge associated with acquired inventory

     —          624   

Costs associated with potential business dispositions

     5,802        6,134   

Costs associated with proxy contest

     —          58   

Impairment and gain (loss) on dispositions, net

     7,104        (761

Loss on sale of equity investment

     —          —     

Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility

     365        364   

Interest accretion associated with acquisition-related compensation charges

     96        99   

Bargain purchase gain associated with the acquisition of the Liberty business

     —          —     

Amortization of acquisition-related intangible assets, restructuring and fair value adjustments to acquisition-related contingent consideration - discontinued operations, net of tax

     7,552        9,205   

Income tax effects on items above

     (16,149     (29,661
  

 

 

   

 

 

 

Non-GAAP adjusted net income available to common stockholders

   $ 59,223      $ 59,264   
  

 

 

   

 

 

 

Net income (loss) per diluted common share from continuing operations

   $ (0.32   $ (0.06

Net loss per diluted common share from discontinued operations

     (0.02     (0.05
  

 

 

   

 

 

 

Net loss per diluted common share

   $ (0.34   $ (0.11
  

 

 

   

 

 

 

Non-GAAP adjusted net income per diluted common share from continuing operations

   $ 0.60      $ 0.63   

Non-GAAP adjusted net income (loss) per diluted common share from discontinued operations

     0.06        0.05   
  

 

 

   

 

 

 

Non-GAAP adjusted net income per diluted common share

   $ 0.66      $ 0.68   
  

 

 

   

 

 

 

Weighted average shares - diluted

     83,586        81,913   
  

 

 

   

 

 

 

Non-GAAP adjusted weighted average shares - diluted

     98,409        96,636   
  

 

 

   

 

 

 

 

(1)  In calculating “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders”, the Company excludes (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from operating income and net income or loss allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust operating income or net income or loss for the costs associated with litigation, including payments made or received through settlements. It should be noted that “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders” are not standard financial measurements under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to operating income and net income or loss or cash flow from operating activities, as a measure of liquidity or as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders” presented in this press release may not be comparable to similar measures used by other companies.


Alere Inc. and Subsidiaries

Reconciliation to Non-GAAP Adjusted Operating Results

(in thousands, except per share amounts)

 

     Year Ended December 31,  
     2014     2013  

Reconciliation to Non-GAAP Adjusted Operating Income (1)

    

Operating income

   $ 93,424      $ 160,404   

Adjustment related to acquired software license contracts

     1,401        2,240   

Amortization of acquisition-related intangible assets

     237,295        280,116   

Restructuring charges

     58,696        14,443   

Stock-based compensation expense

     12,452        21,210   

Compensation charges associated with acquisition-related contingent consideration obligations

     1,855        2,794   

Acquisition-related costs

     874        3,087   

Fair value adjustments to acquisition-related contingent consideration

     12,277        14,736   

Non-cash charge associated with acquired inventory

     —          2,504   

Costs associated with potential business dispositions

     26,565        6,134   

Costs associated with proxy contest

     —          5,525   

Impairment and gain (loss) on dispositions, net

     7,742        5,124   
  

 

 

   

 

 

 

Non-GAAP adjusted operating income

   $ 452,581      $ 518,317   
  

 

 

   

 

 

 
     Year Ended December 31,  
     2014     2013  

Reconciliation to Non-GAAP Adjusted Net Income (1)

    

Net loss available to common stockholders

   $ (186,399   $ (92,547

Adjustment related to acquired software license contracts

     1,401        2,240   

Amortization of acquisition-related intangible assets

     237,341        280,318   

Restructuring charges

     58,738        14,502   

Stock-based compensation expense

     12,452        21,210   

Compensation charges associated with acquisition-related contingent consideration obligations

     1,855        2,794   

Acquisition-related costs

     874        3,087   

Fair value adjustments to acquisition-related contingent consideration

     12,277        14,736   

Non-cash charge associated with acquired inventory

     —          2,504   

Costs associated with potential business dispositions

     26,565        6,134   

Costs associated with proxy contest

     —          5,525   

Impairment and gain (loss) on dispositions, net

     7,742        5,124   

Loss on sale of equity investment

     457        —     

Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility

     1,456        2,490   

Interest accretion associated with acquisition-related compensation charges

     391        357   

Non-cash write-off of an investment

     —          5,110   

Bargain purchase gain associated with the acquisition of the Liberty business

     —          (8,023

Expense associated with extinguishment of debt

     —          35,767   

Amortization of acquisition-related intangible assets, restructuring and fair value adjustments to acquisition-related contingent consideration - discontinued operations, net of tax

     11,776        33,422   

Income tax effects on items above

     (8,894     (126,822
  

 

 

   

 

 

 

Non-GAAP adjusted net income available to common stockholders

   $ 178,032      $ 207,928   
  

 

 

   

 

 

 

Net loss per diluted common share from continuing operations

   $ (2.28   $ (0.92

Net income (loss) per diluted common share from discontinued operations

     0.03        (0.21
  

 

 

   

 

 

 

Net loss per diluted common share

   $ (2.25   $ (1.13
  

 

 

   

 

 

 

Non-GAAP adjusted net income per diluted common share from continuing operations

   $ 1.90      $ 2.24   

Non-GAAP adjusted net income per diluted common share from discontinued operations

     0.17        0.17   
  

 

 

   

 

 

 

Non-GAAP adjusted net income per diluted common share

   $ 2.07      $ 2.41   
  

 

 

   

 

 

 

Weighted average shares - diluted

     82,938        81,542   
  

 

 

   

 

 

 

Non-GAAP adjusted weighted average shares - diluted

     87,397        95,952   
  

 

 

   

 

 

 

 

(1) In calculating “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders”, the Company excludes (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from operating income and net income or loss allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust operating income or net income or loss for the costs associated with litigation, including payments made or received through settlements. It should be noted that “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders” are not standard financial measurements under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to operating income and net income or loss or cash flow from operating activities, as a measure of liquidity or as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “Non-GAAP adjusted operating income” and “Non-GAAP adjusted net income available to common stockholders” presented in this press release may not be comparable to similar measures used by other companies.


Alere Inc. and Subsidiaries

Selected Consolidated Revenues by Business Area (1)

(in thousands)

 

Professional Diagnostics Segment

                               % Change
Q4 14 v. Q4 13
    % Change
YTD 14 v. YTD 13
 
     Q4 2014      YTD 2014      Q4 2013      YTD 2013       

Infectious disease

   $ 203,504       $ 710,514       $ 202,923       $ 723,213         0     -2

Toxicology

     149,241         627,755         151,258         632,727         -1     -1

Cardiology

     109,665         441,582         113,632         463,281         -3     -5

Diabetes

     46,051         197,476         47,350         225,488         -3     -12

Other (1)

     90,271         342,574         85,504         321,495         6     7
  

 

 

    

 

 

    

 

 

    

 

 

      

Professional diagnostics net product sales and services revenue (1)

     598,732         2,319,901         600,667         2,366,204         0     -2

License and royalty revenue

     5,051         19,738         13,415         24,933         -62     -21
  

 

 

    

 

 

    

 

 

    

 

 

      

Professional diagnostics net revenue

   $ 603,783       $ 2,339,639       $ 614,082       $ 2,391,137         -2     -2
  

 

 

    

 

 

    

 

 

    

 

 

      

 

Health Information Solutions Segment

                               % Change
Q4 14 v. Q4 13
    % Change
YTD 14 v. YTD 13
 
     Q4 2014      YTD 2014      Q4 2013      YTD 2013       

Condition and case management

   $ 4,079       $ 16,818       $ 4,119       $ 15,359         -1     9

Wellness

     675         3,499         1,239         5,369         -46     -35

Patient self-testing services

     29,980         116,779         25,483         102,919         18     13
  

 

 

    

 

 

    

 

 

    

 

 

      

Health information solutions net revenue

   $   34,734       $    137,096       $   30,841       $    123,647         13     11
  

 

 

    

 

 

    

 

 

    

 

 

      

 

(1)  Revenues are presented in accordance with generally accepted accounting principles and exclude an adjustment of $0.3 million and $1.4 million, and $0.5 million and $2.2 million related to acquired software license contracts which were not recognized during the three and twelve months ended December 31, 2014 and 2013, respectively, due to business combination accounting rules.


Alere Inc. and Subsidiaries

Reconciliation of Operating Income (Loss) to Non-GAAP Adjusted Operating Income (Loss)

(in thousands)

 

     For the Three Months Ended December 31, 2014  
Operating Segment    Professional
Diagnostics
    Health
Information
Solutions
    Consumer
Diagnostics
    Corporate     Total  

Net revenue

   $ 603,784      $ 34,734      $ 28,339      $ —        $ 666,857   

Adjustment related to acquired software license contracts (1)

     285        —          —          —          285   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted net revenue

   $ 604,069      $ 34,734      $ 28,339      $ —        $ 667,142   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

   $ 44,096      $ (3,226   $ 6,947      $ (12,356   $ 35,461   

Adjustment related to acquired software license contracts (1)

     285        —          —          —          285   

Amortization of acquisition-related intangible assets

     63,006        1,138        (2,168     (1,290     60,686   

Restructuring charges

     14,701        13        —          6,908        21,622   

Stock-based compensation expense

     —          —          —          4,701        4,701   

Compensation charges associated with acquisition-related contingent consideration obligations

     182        —          —          —          182   

Acquisition-related costs

     —          —          —          179        179   

Fair value adjustments to acquisition-related contingent consideration

     1,435        600        —          (6,800     (4,765

Costs associated with potential business dispositions

     133        5,669        —          —          5,802   

Impairment and gain (loss) on dispositions, net

     7,104        —          —          —          7,104   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted operating income (loss)

   $ 130,942      $ 4,194      $ 4,779      $ (8,658   $ 131,257   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted operating income (loss) as % of Non-GAAP adjusted net revenue

     21.7     12.1     16.9       19.7
  

 

 

   

 

 

   

 

 

     

 

 

 

 

(1) Estimated revenue related to acquired software license contracts that was not recognized during the fourth quarter of 2014 due to business combination accounting rules.

 

     For the Three Months Ended December 31, 2013  
Operating Segment    Professional
Diagnostics
    Health
Information
Solutions
    Consumer
Diagnostics
    Corporate     Total  

Net revenue

   $ 614,082      $ 30,841      $ 28,232      $ —        $ 673,155   

Adjustment related to acquired software license contracts (1)

     470        —          —          —          470   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted net revenue

   $ 614,552      $ 30,841      $ 28,232      $ —        $ 673,625   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

   $ 70,161      $ (3,333   $ 3,091      $ (23,546   $ 46,373   

Adjustment related to acquired software license contracts (1)

     470        —          —          —          470   

Amortization of acquisition-related intangible assets

     69,894        (5     458        —          70,347   

Non-cash charge associated with acquired inventory

     624        —          —          —          624   

Restructuring charges

     3,444        774        —          —          4,218   

Stock-based compensation expense

     —          —          —          6,748        6,748   

Compensation charges associated with acquisition-related contingent consideration obligations

     762        —          —          —          762   

Acquisition-related costs

     —          —          —          1,315        1,315   

Fair value adjustments to acquisition-related contingent consideration

     (2,859     1,100        —          200        (1,559

Costs associated with proxy contest

     —          —          —          58        58   

Costs associated with potential business dispositions

     6,134        —          —          —          6,134   

Gain on disposition

     (761     —          —          —          (761
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted operating income (loss)

   $ 147,869      $ (1,464   $ 3,549      $ (15,225   $ 134,729   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted operating income (loss) as % of Non-GAAP adjusted net revenue

     24.1     -4.7     12.6       20.0
  

 

 

   

 

 

   

 

 

     

 

 

 

 

(1) Estimated revenue related to acquired software license contracts that was not recognized during the fourth quarter of 2013 due to business combination accounting rules.

Comments:

In calculating “Non-GAAP adjusted operating income (loss)” in the schedule presented above, the Company excludes from “Operating income (loss)” (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from “Operating income (loss)” allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust “Operating income (loss)” for the costs associated with litigation, including payments made or received through settlements. It should be noted that “Non-GAAP adjusted operating income (loss)” is not a standard financial measurement under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to “Operating income (loss)” as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “Non-GAAP adjusted operating income (loss)” presented in this schedule may not be comparable to similar measures used by other companies.

Reference should also be made to the Company’s financial results contained in our earnings press release respective to the periods presented in this schedule, which include a more detailed discussion of the adjustments to the GAAP operating results presented above.


Alere Inc. and Subsidiaries

Reconciliation of Operating Income (Loss) to Non-GAAP Adjusted Operating Income (Loss)

(in thousands)

 

     For the Year Ended December 31, 2014  
Operating Segment    Professional
Diagnostics
    Health
Information
Solutions
    Consumer
Diagnostics
    Corporate     Total  

Net revenue

   $ 2,339,639      $ 137,096      $ 109,955      $ —        $ 2,586,690   

Adjustment related to acquired software license contracts (1)

     1,401        —          —          —          1,401   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted net revenue

   $ 2,341,040      $ 137,096      $ 109,955      $ —        $ 2,588,091   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

   $ 163,434      $ (1,197   $ 17,566      $ (86,379   $ 93,424   

Adjustment related to acquired software license contracts (1)

     1,401        —          —          —          1,401   

Amortization of acquisition-related intangible assets

     233,693        5,089        (1,530     43        237,295   

Restructuring charges

     44,272        188        —          14,236        58,696   

Stock-based compensation expense

     —          —          —          12,452        12,452   

Compensation charges associated with acquisition-related contingent consideration obligations

     1,855        —          —          —          1,855   

Acquisition-related costs

     —          —          —          874        874   

Fair value adjustments to acquisition-related contingent consideration

     18,238        (2,561     —          (3,400     12,277   

Costs associated with potential business dispositions

     20,578        5,987        —          —          26,565   

Impairment and gain (loss) on dispositions, net

     7,742        —          —          —          7,742   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted operating income (loss)

   $ 491,213      $ 7,506      $ 16,036      $ (62,174   $ 452,581   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted operating income (loss) as % of Non-GAAP adjusted net revenue

     21.0     5.5     14.6       17.5
  

 

 

   

 

 

   

 

 

     

 

 

 

 

(1) Estimated revenue related to acquired software license contracts that was not recognized during the year ended December 31, 2014 due to business combination accounting rules.

 

     For the Year Ended December 31, 2013  
Operating Segment    Professional
Diagnostics
    Health
Information
Solutions
    Consumer
Diagnostics
    Corporate     Total  

Net revenue

   $ 2,391,137      $ 123,647      $ 105,078      $ —        $ 2,619,862   

Adjustment related to acquired software license contracts (1)

     2,240        —          —          —          2,240   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted net revenue

   $ 2,393,377      $ 123,647      $ 105,078      $ —        $ 2,622,102   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

   $ 256,086      $ (17,349   $ 12,122      $ (90,455   $ 160,404   

Adjustment related to acquired software license contracts (1)

     2,240        —          —          —          2,240   

Amortization of acquisition-related intangible assets

     271,711        6,494        1,911        —          280,116   

Restructuring charges

     12,606        1,837        —          —          14,443   

Stock-based compensation expense

     —          —          —          21,210        21,210   

Compensation charges associated with acquisition-related contingent consideration obligations

     2,794        —          —          —          2,794   

Non-cash charge associated with acquired inventory

     2,504        —          —          —          2,504   

Acquisition-related costs

     —          —          —          3,087        3,087   

Fair value adjustments to acquisition-related contingent consideration

     10,050        3,586        —          1,100        14,736   

Costs associated with proxy contest

     —          —          —          5,525        5,525   

Costs associated with potential business dispositions

     6,134        —          —          —          6,134   

Loss on disposition

     5,124        —          —          —          5,124   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted operating income (loss)

   $ 569,249      $ (5,432   $ 14,033      $ (59,533   $ 518,317   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP adjusted operating income (loss) as % of Non-GAAP adjusted net revenue

     23.8     -4.4     13.4       19.8
  

 

 

   

 

 

   

 

 

     

 

 

 

 

(1) Estimated revenue related to acquired software license contracts that was not recognized during the year ended December 31, 2013 due to business combination accounting rules.

Comments:

In calculating “Non-GAAP adjusted operating income (loss)” in the schedule presented above, the Company excludes from “Operating income (loss)” (i) certain non-cash charges, including amortization expense and stock-based compensation expense, (ii) non-recurring charges and income, and (iii) certain other charges and income that have a significant positive or negative impact on results yet do not occur on a consistent or regular basis in its business. In determining whether a particular item meets one of these criteria, management considers facts and circumstances that it believes are relevant. Management believes that excluding such charges and income from “Operating income (loss)” allows investors and management to evaluate and compare the Company’s operating results from continuing operations from period to period in a meaningful and consistent manner. Due to the frequency of their occurrence in its business, the Company does not adjust “Operating income (loss)” for the costs associated with litigation, including payments made or received through settlements. It should be noted that “Non-GAAP adjusted operating income (loss)” is not a standard financial measurement under accounting principles generally accepted in the United States of America (“GAAP”) and should not be considered as an alternative to “Operating income (loss)” as an indicator of operating performance or any measure of performance derived in accordance with GAAP. In addition, all companies do not calculate non-GAAP financial measures in the same manner and, accordingly, “Non-GAAP adjusted operating income (loss)” presented in this schedule may not be comparable to similar measures used by other companies.

Reference should also be made to the Company’s financial results contained in our earnings press release respective to the periods presented in this schedule, which include a more detailed discussion of the adjustments to the GAAP operating results presented above.


Alere Inc. and Subsidiaries

Reconciliations to Non-GAAP Adjusted P&L Categories

(in thousands)

 

     Three Months Ended
December 31, 2014
    Three Months Ended
December 31, 2013
 

Net revenue

   $ 666,857      $ 673,155   

Adjustment related to acquired software license contracts

     285        470   
  

 

 

   

 

 

 

Non-GAAP adjusted net revenue

   $ 667,142      $ 673,625   
  

 

 

   

 

 

 

Cost of net revenue

   $ 356,526      $ 331,217   

Less adjustments:

    

Amortization of acquisition-related intangible assets

     (17,269     (15,328

Restructuring charges

     (5,053     (2,253

Stock-based compensation expense

     (317     (329

Non-cash charge associated with acquired inventory

     —          (624
  

 

 

   

 

 

 

Non-GAAP adjusted cost of net revenue

   $ 333,887      $ 312,683   
  

 

 

   

 

 

 

Non-GAAP adjusted gross profit

   $ 333,255      $ 360,942   
  

 

 

   

 

 

 
     Three Months Ended
December 31, 2014
    Three Months Ended
December 31, 2013
 

Research and development

   $ 29,973      $ 38,324   

Less adjustments:

    

Amortization of acquisition-related intangible assets

     (2,755     (1,206

Restructuring charges

     (1,312     (50

Stock-based compensation expense

     (299     (1,413
  

 

 

   

 

 

 

Non-GAAP adjusted research and development

   $ 25,607      $ 35,655   
  

 

 

   

 

 

 
     Three Months Ended
December 31, 2014
    Three Months Ended
December 31, 2013
 

Selling, general and administrative

   $ 237,793      $ 258,002   

Less adjustments:

    

Amortization of acquisition-related intangible assets

     (40,662     (53,813

Restructuring charges

     (15,257     (1,915

Stock-based compensation expense

     (4,085     (5,006

Compensation charges associated with acquisition-related contingent consideration obligations

     (182     (762

Acquisition-related costs

     (179     (1,315

Fair value adjustments to acquisition-related contingent consideration

     4,765        1,559   

Costs associated with potential business dispositions

     (5,802     (6,134

Costs associated with proxy contest

     —          (58
  

 

 

   

 

 

 

Non-GAAP adjusted selling, general and administrative

   $ 176,391      $ 190,558   
  

 

 

   

 

 

 
     Three Months Ended
December 31, 2014
    Three Months Ended
December 31, 2013
 

Impairment and gain (loss) on dispositions, net

   $ 7,104      $ (761

Impairment and gain (loss) on dispositions, net

     (7,104     761   
  

 

 

   

 

 

 

Non-GAAP adjusted impairment and gain (loss) on dispositions, net

   $ —        $ —     
  

 

 

   

 

 

 
     Three Months Ended
December 31, 2014
    Three Months Ended
December 31, 2013
 

Interest and other income (expense), net

   $ (55,889   $ (56,293

Less adjustments:

    

Restructuring charges

     8        13   

Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility

     365        364   

Interest accretion associated with acquisition-related compensation charges

     96        99   
  

 

 

   

 

 

 

Non-GAAP adjusted interest and other income (expense), net

   $ (55,420   $ (55,817
  

 

 

   

 

 

 
     Three Months Ended
December 31, 2014
    Three Months Ended
December 31, 2013
 

Provision (benefit) for income taxes

   $ 4,836      $ (7,082

Add: Income tax effects on Non-GAAP adjustments

     16,172        29,710   
  

 

 

   

 

 

 

Non-GAAP adjusted provision for income taxes

   $ 21,008      $ 22,628   
  

 

 

   

 

 

 
     Three Months Ended
December 31, 2014
    Three Months Ended
December 31, 2013
 

Equity earnings of unconsolidated entities, net of tax

   $ 3,793      $ 4,205   

Less adjustments:

    

Amortization of acquisition-related intangible assets

     97        146   

Income tax effects on items above

     —          —     
  

 

 

   

 

 

 

Non-GAAP adjusted equity earnings of unconsolidated entities, net of tax

   $ 3,890      $ 4,351   
  

 

 

   

 

 

 


Alere Inc. and Subsidiaries

Reconciliations to Non-GAAP Adjusted P&L Categories

(in thousands)

 

     Year Ended December 31,
2014
    Year Ended December 31,
2013
 

Net revenue

   $ 2,586,690      $ 2,619,862   

Adjustment related to acquired software license contracts

     1,401        2,240   
  

 

 

   

 

 

 

Non-GAAP adjusted net revenue

$ 2,588,091    $ 2,622,102   
  

 

 

   

 

 

 

Cost of net revenue

$ 1,364,786    $ 1,297,485   

Less adjustments:

Amortization of acquisition-related intangible assets

  (64,511   (68,106

Restructuring charges

  (11,760   (6,145

Stock-based compensation expense

  (1,180   (1,126

Non-cash charge associated with acquired inventory

  —        (2,504
  

 

 

   

 

 

 

Non-GAAP adjusted cost of net revenue

$ 1,287,335    $ 1,219,604   
  

 

 

   

 

 

 

Non-GAAP adjusted gross profit

$ 1,300,756    $ 1,402,498   
  

 

 

   

 

 

 
     Year Ended December 31,
2014
    Year Ended December 31,
2013
 

Research and development

   $ 144,828      $ 159,053   

Less adjustments:

    

Amortization of acquisition-related intangible assets

     (6,476     (4,935

Restructuring charges

     (9,800     (1,795

Stock-based compensation expense

     41        (4,054
  

 

 

   

 

 

 

Non-GAAP adjusted research and development

$ 128,593    $ 148,269   
  

 

 

   

 

 

 
     Year Ended December 31,
2014
    Year Ended December 31,
2013
 

Selling, general and administrative

   $ 975,910      $ 997,796   

Less adjustments:

    

Amortization of acquisition-related intangible assets

     (166,308     (207,075

Restructuring charges

     (37,136     (6,503

Stock-based compensation expense

     (11,313     (16,030

Compensation charges associated with acquisition-related contingent consideration obligations

     (1,855     (2,794

Acquisition-related costs

     (874     (3,087

Fair value adjustments to acquisition-related contingent consideration

     (12,277     (14,736

Costs associated with potential business dispositions

     (26,565     (6,134

Costs associated with proxy contest

     —          (5,525
  

 

 

   

 

 

 

Non-GAAP adjusted selling, general and administrative

$ 719,582    $ 735,912   
  

 

 

   

 

 

 
     Year Ended December 31,
2014
    Year Ended December 31,
2013
 

Impairment and gain (loss) on dispositions, net

   $ 7,742      $ 5,124   

Impairment and gain (loss) on dispositions, net

     (7,742     (5,124
  

 

 

   

 

 

 

Non-GAAP adjusted impairment and gain (loss) on dispositions, net

$ —      $ —     
  

 

 

   

 

 

 
     Year Ended December 31,
2014
    Year Ended December 31,
2013
 

Interest and other income (expense), net

   $ (211,924   $ (266,605

Less adjustments:

    

Restructuring charges

     42        59   

Interest expense recorded in connection with fees paid for certain debt modifications and the termination of our senior secured credit facility

     1,456        2,490   

Interest accretion associated with acquisition-related compensation charges

     391        357   

Non-cash write-off of an investment

     —          5,110   

Bargain purchase gain associated with the acquisition of the Liberty business

     —          (8,023

Expense associated with extinguishment of debt

     —          35,767   
  

 

 

   

 

 

 

Non-GAAP adjusted interest and other income (expense), net

$ (210,035 $ (230,845
  

 

 

   

 

 

 
     Year Ended December 31,
2014
    Year Ended December 31,
2013
 

Provision (benefit) for income taxes

   $ 66,722      $ (35,359

Add: Income tax effects on Non-GAAP adjustments

     9,005        126,914   
  

 

 

   

 

 

 

Non-GAAP adjusted provision for income taxes

$ 75,727    $ 91,555   
  

 

 

   

 

 

 
     Year Ended December 31,
2014
    Year Ended December 31,
2013
 

Equity earnings of unconsolidated entities, net of tax

   $ 17,509      $ 17,443   

Less adjustments:

    

Amortization of acquisition-related intangible assets

     527        594   

Loss on sale of equity investment

     457        —     

Income tax effects on items above

     —          —     
  

 

 

   

 

 

 

Non-GAAP adjusted equity earnings of unconsolidated entities, net of tax

$ 18,493    $ 18,037   
  

 

 

   

 

 

 


Alere Inc. and Subsidiaries

Reconciliations of Gross Profit/Margin to Non-GAAP Adjusted Gross Profit/Margin

(in thousands)

 

Alere Consolidated    Three Months Ended
December 31, 2013 (1)
    Three Months Ended
September 30, 2014 (1)
    Three Months Ended
December 31, 2014
 

Net revenue

   $ 673,155        $ 647,435         $ 666,857      

Adjustment related to acquired software license contracts

     470          324           285      
  

 

 

     

 

 

      

 

 

    

Non-GAAP adjusted net revenue

     673,625          647,759           667,142      
  

 

 

     

 

 

      

 

 

    

Cost of net revenue

     331,217          346,513           356,526      

Less adjustments:

              

Amortization of acquisition-related intangible assets

     15,328          15,683           17,269      

Stock-based compensation expense

     329          291           317      

Non-cash charge associated with acquired inventory

     624          —             —        

Restructuring charges

     2,253          5,654           5,053      
  

 

 

     

 

 

      

 

 

    

Non-GAAP adjusted cost of net revenue

     312,683          324,885           333,887      
  

 

 

     

 

 

      

 

 

    

Non-GAAP adjusted gross profit/margin

   $ 360,942        53.6   $ 322,874         49.8   $ 333,255         50.0
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 
Professional Diagnostics Segment    Three Months Ended
December 31, 2013
    Three Months Ended
September 30, 2014
    Three Months Ended
December 31, 2014
 

Net product sales and services revenue

   $ 600,667        $ 581,759         $ 598,732      

Adjustment related to acquired software license contracts

     470          324           285      
  

 

 

     

 

 

      

 

 

    

Non-GAAP adjusted net product sales and services revenue

     601,137          582,083           599,017      
  

 

 

     

 

 

      

 

 

    

Cost of net revenue

     292,183          308,467           314,933      

Less adjustments:

              

Amortization of acquisition-related intangible assets

     16,005          15,081           16,747      

Stock-based compensation expense

     329          291           317      

Non-cash charge associated with acquired inventory

     624          —             —        

Restructuring charges

     2,253          5,654           5,053      
  

 

 

     

 

 

      

 

 

    

Non-GAAP adjusted cost of net revenue

     272,972          287,441           292,816      
  

 

 

     

 

 

      

 

 

    

Non-GAAP adjusted gross profit/margin

   $ 328,165        54.6   $ 294,642         50.6   $ 306,201         51.1
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 
Health Information Solutions Segment    Three Months Ended
December 31, 2013 (1)
    Three Months Ended
September 30, 2014 (1)
    Three Months Ended
December 31, 2014
 

Net product sales and services revenue

   $ 30,841        $ 35,046         $ 34,734      
  

 

 

     

 

 

      

 

 

    

Cost of net revenue

     14,020          16,596           17,891      

Less adjustments:

              

Amortization of acquisition-related intangible assets

     (888       577           497      

Restructuring charges

     —            —             —        
  

 

 

     

 

 

      

 

 

    

Non-GAAP adjusted cost of net revenue

     14,908          16,019           17,394      
  

 

 

     

 

 

      

 

 

    

Non-GAAP adjusted gross profit/margin

   $ 15,933        51.7   $ 19,027         54.3   $ 17,340         49.9
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Note:

 

(1)  Restated to reflect the impact of discontinued operations


Alere Inc. and Subsidiaries

Reconciliation of Net Loss to Non-GAAP EBITDA

(in thousands)

 

     Three Months Ended
December 31, 2014
    Year Ended
December 31, 2014
 

Net Loss (1)

   $ (22,915   $ (165,076

Less: Income (loss) from discontinued operations, net of tax

     (1,444     2,637   
  

 

 

   

 

 

 

Loss from continuing operations

     (21,471     (167,713

Adjustment related to acquired software license contracts

     285        1,401   

Income tax provision

     4,836        66,722   

Depreciation and amortization

     85,163        336,360   

Interest, net

     51,969        206,800   

Non-cash stock-based compensation expense

     4,701        12,452   

Non-cash fair value adjustments to acquisition-related contingent consideration

     (4,765     12,277   

Loss on sale of equity investment

     —          457   

Impairment and gain (loss) on dispositions, net

     7,104        7,742   
  

 

 

   

 

 

 

Non-GAAP EBITDA

   $ 127,822      $ 476,498   
  

 

 

   

 

 

 

 

(1) Net loss for the three months and year ended December 31, 2014 includes non-interest related restructuring charges of $21.6 million and $58.7 million, respectively; $0.2 million and $0.9 million, respectively, of acquisition costs and $5.8 million and $26.6 million, respectively, of costs associated with potential business dispositions which have not been added back for purposes of computing Non-GAAP EBITDA.


Alere Inc. and Subsidiaries

Discontinued Operations

(in thousands)

 

    Three
Months
Ended
March 31,
2013
    Three
Months
Ended
June 30,
2013
    Three Months
Ended
September 30,
2013
    Three
Months
Ended
December 31,
2013
    Three
Months
Ended
March 31,
2014
    Three
Months
Ended
June 30,
2014
    Three Months
Ended
September 30,
2014
    Three
Months
Ended
December 31,
2014
 

Net product sales and services revenue

  $ 103,776      $ 104,002      $ 102,630      $ 99,171      $ 91,382      $ 90,786      $ 89,501      $ 87,827   

License and royalty revenue

    —          —          —          —        $ —        $ —        $ —        $ —     
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

    103,776        104,002        102,630        99,171      $ 91,382      $ 90,786      $ 89,501      $ 87,827   

Cost of net revenue

    60,488        57,339        55,630        56,760      $ 51,420      $ 50,240      $ 54,314      $ 47,140   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit (loss)

    43,288        46,663        47,000        42,411      $ 39,962      $ 40,546      $ 35,187      $ 40,687   

Operating expenses:

               

Research and development

    968        736        20        26      $ —        $ —        $ —        $ —     

Sales and marketing

    19,427        18,488        17,840        17,944      $ 14,020      $ 14,862      $ 14,269      $ 13,657   

General and administrative

    31,522        34,525        32,264        31,254      $ 30,121      $ 28,198      $ 16,925      $ 24,139   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating loss

    (8,629     (7,086     (3,124     (6,813   $ (4,179   $ (2,514   $ 3,993      $ 2,891   

Interest and other income (expense), net

    (254     (397     (584     (943   $ (695   $ (629   $ (266   $ (715
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Loss before benefit for income taxes

    (8,883     (7,483     (3,708     (7,756   $ (4,874   $ (3,143   $ 3,727      $ 2,176   

Provision (benefit) for income taxes

    (3,521     (2,924     (1,429   $ (3,077   $ (1,948   $ (1,047   $ (5,376   $ 3,620   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from discontinued operations, net of taxes

  $ (5,362   $ (4,559   $ (2,279   $ (4,679   $ (2,926   $ (2,096   $ 9,103      $ (1,444
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Certain items included above:

               

Amortization of intangible assets:

               

Cost of net revenue

  $ 313      $ 837      $ 580      $ 2,328      $ 760      $ 761      $ 18,719      $ 289   

Sales and marketing

    7,918        7,968        7,943        7,937        6,125        6,125        6,125        6,088   

General and administrative

    625        631        688        628        628        628        654        625   

Change in fair value of contingent consideration:

               

General and administrative

    1,700        100        900        600        (1,350     100        (25,071     —     

Restructuring

               

Cost of net revenue

    411        531        74        704        42        72        —          11   

Sales and marketing

    574        12          635        7            4   

General and administrative

    911        5,409        1,483        2,179        2,768        378        430        (9

Interest and other income (expense), net

    39        47        97        70        113        97        132        93   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
    12,491        15,535        11,765        15,081        9,093        8,161        989        7,101   

Provision for income taxes

    (4,892     (6,079     (4,604     (5,876     (3,559     (3,190     (7,270     (2,783
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $ 7,599      $ 9,456      $ 7,161      $ 9,205      $ 5,534      $ 4,971      $ (6,281   $ 4,318